LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

Search

Avita Therapeutics Inc

Open

6.55 6.33

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

6.16

Max

6.63

Schlüsselkennzahlen

By Trading Economics

Einkommen

-2.3M

-14M

Verkäufe

108K

19M

EPS

-0.826

Gewinnspanne

-74.857

Angestellte

260

EBITDA

-9.9M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+152.32% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

7. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-52M

192M

Vorheriger Eröffnungskurs

0.22

Vorheriger Schlusskurs

6.55

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Avita Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

15. Mai 2025, 22:52 UTC

Ergebnisse
Wichtige Markttreiber

Virgin Galactic Shares Rise on Commercial Spaceflight Plans, Narrower 1Q Loss

15. Mai 2025, 20:37 UTC

Top News
Ergebnisse

Applied Materials Logs Higher 2Q Profit, Revenue as Customer Demand Remains Unchanged

16. Mai 2025, 00:00 UTC

Market Talk

Xero Bull Stays Positive on Cost Outlook -- Market Talk

15. Mai 2025, 23:47 UTC

Market Talk

Gold Consolidates; Likely Supported by Signs of Disinflation -- Market Talk

15. Mai 2025, 23:38 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. Mai 2025, 23:38 UTC

Market Talk

Nikkei May Edge Higher, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15. Mai 2025, 23:14 UTC

Top News

Walmart Becomes Biggest Retailer Yet to Pass Through Tariff Price Increases -- 4th Update

15. Mai 2025, 22:46 UTC

Top News
Akquisitionen, Fusionen, Übernahmen

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15. Mai 2025, 22:46 UTC

Akquisitionen, Fusionen, Übernahmen

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

15. Mai 2025, 22:46 UTC

Akquisitionen, Fusionen, Übernahmen

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

15. Mai 2025, 22:46 UTC

Akquisitionen, Fusionen, Übernahmen

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15. Mai 2025, 21:58 UTC

Ergebnisse

Applied Materials Earnings Beat Expectations. Why the Stock Is Down. -- Barrons.com

15. Mai 2025, 21:24 UTC

Ergebnisse

Cava's Earnings Beat Expectations. Growth Was Strong Despite Tariff Fears. -- Barrons.com

15. Mai 2025, 20:56 UTC

Market Talk

U.S. Spending Downturn Could Lie Ahead -- Market Talk

15. Mai 2025, 20:54 UTC

Market Talk
Ergebnisse

Applied Materials CFO Says Demand Stable Despite Tariffs, Macro -- Market Talk

15. Mai 2025, 20:54 UTC

Ergebnisse

Applied Materials Investing to Support Semiconductor Market of More Than $1T by End of Decade, Financial Chief Says

15. Mai 2025, 20:51 UTC

Ergebnisse

Applied Materials Financial Chief: Long-Term Secular Growth Drivers Remain Intact

15. Mai 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

15. Mai 2025, 20:50 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire Sells Financial Stocks, Doubles Constellation Stake, Holds Steady on Apple -- WSJ

15. Mai 2025, 20:50 UTC

Ergebnisse

Applied Materials' Customer Investments Continue at Expected Rate and Pace, Financial Chief Says

15. Mai 2025, 20:47 UTC

Ergebnisse

Applied Materials Not Currently Seeing Large Changes in Customer Demand, CEO Says

15. Mai 2025, 20:47 UTC

Ergebnisse

Applied Materials Sees Revenue From Advanced DRAM Customers to Grow 40% in FY25, CEO Says

15. Mai 2025, 20:47 UTC

Ergebnisse

Applied Materials Grew Faster Than Peers in Markets Outside China in 2Q, CEO Says

15. Mai 2025, 20:47 UTC

Ergebnisse

Applied Materials Underperformed Market in China in 2Q Due to Restrictions on U.S. Companies, CEO Says

15. Mai 2025, 20:37 UTC

Ergebnisse

SOS Ltd: Growth Was Fueled by Robust Domestic Demand and Expansion of Pdt Portfolio to Include Rubber and Coal >SOS

15. Mai 2025, 20:37 UTC

Ergebnisse

SOS Ltd: Cryptocurrency Mining Rev Declined to $9.3M From $18.9M in FY23, Dip Was Attributed to the Temporary Shutdown of Texas Mining Facility for Upgrades During 1H 2024 >SOS

15. Mai 2025, 20:37 UTC

Ergebnisse

SOS Ltd: FY24 Significant Yr-over-Yr Increase in Commodity Trading Rev, Which Soared to $214.3M FY24, 92.6% of Total Rev Up From 74.0% in FY23 >SOS

15. Mai 2025, 20:37 UTC

Ergebnisse

SOS Ltd: Cryptocurrency Mining Rev Halves as SOS Focuses on Facility Upgrades and Commodity Expansion >SOS

15. Mai 2025, 20:26 UTC

Top News

Trump Presses Apple to Bring iPhone Manufacturing to America. Wall Street Shrugs. -- WSJ

15. Mai 2025, 20:25 UTC

Ergebnisse

Deere Stock Jumps on Guidance Cut. Here's Why. -- Barrons.com

Peer-Vergleich

Kursveränderung

Avita Therapeutics Inc Prognose

Kursziel

By TipRanks

152.32% Vorteil

12-Monats-Prognose

Durchschnitt 16.88 USD  152.32%

Hoch 22 USD

Tief 12.5 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Avita Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

4 ratings

4

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

8.83 / 9.77Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Weak Bearish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Avita Therapeutics Inc

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.